Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Milei Threatens Falkland Oil Firms With Sanctions 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
OpenAI Rejects Apple Trade Secret Theft Claims 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
CAMBRIDGE, Mass., March 05, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Cowen 38th Annual Healthcare Conference in Boston on Monday, March 12, 2018 at 11:20 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Pharmaceuticals:
Renee Leck, 617-649-8299
Senior Manager, Investor & Public Relations
[email protected]
